Search Results

The GPCR Data Dilemma: The Lego Bucket Problem I've seen promising GPCR programs generate massive volumes Systems That Drive Progress:  From assay tracking to data workflows, I design simple, scalable tools GPCR As the co-founder of Dr. GPCR, we've built a global hub connecting over 1,300 GPCR scientists dedicated to this field. Ready to Move Your GPCR Program Forward?

Read the article now ➤ Discovery on Target - The Next Wave of GPCR Drug Discovery The 20th Annual GPCR-Based Drug Discovery Conference  isn’t just another event—it’s where the frameworks shaping the next decade GPCR Premium Membership Gives You an Edge The GPCR field is advancing at breakneck speed. The pace of GPCR innovation is accelerating. Aside from his vast experience in drug development, not to mention his extensive publication record,

content — designed to keep you ahead without noise or delays: Industry insights:  Structure-Based Drug Design Summit; AI-Powered GPCR Research; Lab-in-the-Loop Hit Discovery advances. Must-read publications:  GPCRchimeraDB: Database of engineered GPCR designs. lectures, classified industry news, priority event alerts, job opportunities, and insider commentary—all designed GPCR Premium is designed for scientists who need the right intelligence, fast—without noise, distractions

safety, efficacy, and design decisions. the next generation of GPCR ligands? You’re not just designing for receptor activity—you’re designing for enzyme survival. Kenakin live for an open Q&A session designed for discovery scientists. design.

Innovative design approach emphasizing scientific principles over speculation. GPCR News delivers a toolkit of practical innovations—from drug design strategies that anticipate physiological Terry's Corner – Designing Drugs That Anticipate Physiological Pushback Most GPCR programs don’t fail GPCR , our mission is simple but urgent: Accelerate GPCR biology and drug discovery by connecting scientists field 🧠 Designed for researchers at every career stage

Terry's Corner : Unlock the Power of Intracellular GPCR Drugs For years, GPCR drug discovery has focused GPCR Podcast : The Future of GPCR Drug Discovery with Molecular Modeling The field of GPCR research is This research topic is designed to stimulate discussion and fuel the scientific direction of future GPCR , classified industry news, priority event alerts, job opportunities, and insider commentary—designed GPCR scientists, translational pharmacologists, biotech drug discovery teams, and decision-makers who

In the high-stakes world of GPCR drug discovery , breakthrough science isn't enough. GPCR, we recognized this core problem. The Role of Systems Thinking in GPCR Drug Discovery Systems thinking is the intentional practice of seeing I'll show you how to transform your drug discovery process from a series of disconnected efforts into The GPCR Precision Blueprint is more than a concept.

Why Speed Matters in GPCR Drug Discovery Nine out of ten GPCR programs stall  not because the target Screening technologies, structure-informed design, and AI are accelerating target selection. Terry’s Corner is designed to shorten that distance between initial promise and actionable clarity. This expands the strategic toolbox for discovery teams: Bias isn’t an “optional property” to design in design.

Drugs Change the Game For decades, drug design has treated GPCRs as surface targets. You get longer activity with shorter exposure—a dream scenario for drug designers. how this plays out in model systems and clinical data—and why residence time should be a first-class design He also reviews key scaffold properties that determine success, offering practical tips for design teams And while orthosteric ligands may never reach them, properly designed intracellular drugs can.

Over 30% of FDA-approved drugs target GPCRs, with many targeting CNS located GPCRs. key in drug design. Emerging GPCR Therapeutic Targets in CNS Drug Discovery GPCRs have been studied for decades, but there Both orphan and well-characterized GPCRs are untapped opportunities for drug development targeting CNS Advantages of Fluorescent Ligands in GPCR Drug Screening for CNS Choosing the right tools is important

with built-in selectivity and context sensitivity Why GPCR Allosteric Thinking Changes the Game in Drug Unexpected activity profiles, SAR that breaks your QSAR model, and missed opportunities to design more This has direct implications for: Assay timing and readout design Misclassification of lead candidates But without understanding how GPCR state changes  influence that affinity—or vice versa—drug discovery modulators, the principles in this lecture equip you to design ligands that not only bind, but bind

In GPCR drug discovery, a single mistaken assumption can derail an entire program. Why Misreading Antagonism Delays GPCR Drug Discovery If a dose-response curve shifts to the right, you Monthly Ask‑Me‑Anything sessions with live Q&A An expanding on‑demand library for novices to expert drug hunters Influence over upcoming topics Who it’s for:  drug discovery teams, pharmacologists refining Why now:  GPCR research is accelerating—and the projects that succeed will be those built on clear, accurate

GPCR research requires turning data into insights for drug discovery Hi GPCR Friends, Every week, critical drug strategies shifting; antibody pharmacology opening fresh doors. Terry's Corner – Curve Shifts Don’t Lie, But Your Eyes Might In early drug discovery, “those curves look Understand how AI/ML and GPCR biology meet to unlock safer drugs. lectures, classified industry news, priority event alerts, job opportunities, and insider commentary—designed

Design for translation:  Map sensitivity ranges to tissue contexts so your plate data predicts what happens Watch our new trailers for a preview of expert-led GPCR training designed for scientists and drug hunters drug discovery. But behind every “new” assay is a decade of design, failure, and rethinking. field 🧠 Designed for researchers at every career stage

trials derail. ✅ Practical strategies  for using receptor trafficking data and system set-points to design Every ligand you design enters a system that is already balancing opposing forces—vasoconstriction vs Reflexes as Drug Design Partners Not all reflexes are enemies. Some can make a mediocre drug shine. The teaser question How could you design your next lead to recruit the body’s own feedback loops in your This section raises a critical design question for teams Are you sure your “antagonist” is enough—or

The power of this design lies not in its independence but in its interdependence . And experiments are better designed because expectations are realistic. The most effective discovery programs are structured like Carlsson’s: modeling designed with downstream And he prioritizes shared purpose , designing each project with the next experiment in mind. GPCR Models Don’t Discover Drugs—People Do In GPCR research, the biggest breakthroughs won’t come from

GPCR – Precision Tools for GPCR Assays Dr. GPCR and Celtarys Research have teamed up. features a discussion about a scalable GPCR-RAMP assay. Their global resource is now helping labs decode GPCR biology at scale. It’s exciting to see how the GPCR field is evolving. GPCR Team

GPCR and global experts at the GPCR Drug Discovery session during Discovery on Target 2025—where groundbreaking GPCR Drug Discovery at Discovery on Target 2025 — The Track You Can’t Miss If you work in drug discovery Structure-based design  powered by cryo-EM and AI. 🔬 Inside the GPCR Track Agenda Expect deep dives design strategy. Let’s move GPCR drug discovery forward — together. 🚨 Mark your calendar for the GPCR Happy Hour Join

Masterclass on GPCR Allostery: Unveiling Techniques to Decode Drug Behavior – July 31st, 2025. Welcome back GPCR fans, If your drug discovery strategy still relies on static GPCR models, you’re already Some drugs take hours to reach equilibrium—not because of poor design, but because the system is fluid Why you need to be there: Learn how kinetic nuance shapes ligand design.   lectures, classified industry news, priority event alerts, job opportunities, and insider commentary—designed

Is Your GPCR Program Slowing Down—Even With Good Data? You’re not alone. Meetings drag. Decisions stall. And momentum quietly dies. GPCR Ecosystem. Strong science. Promising data. But no systems to turn it into momentum. Here’s what I bring: Biology-First Strategy I’ve designed GPCR assays, led collaborations across research GPCR, I’m connected to 1,300+ scientists and decision-makers worldwide.

GPCR. of GPCR research and drug discovery. Terry's Corner - Unlock the Power of Target Residence Time in Your GPCR Drug Discovery Pipeline Gain Designed for GPCR scientists and translational teams, Premium keeps you informed on the science, careers , and business moves shaping drug discovery.

Innovative Approaches in GPCR Drug Discovery: Designing Precise Solutions for GPCR Challenges. That’s exactly what Terry’s Corner delivers this week: a deep dive into molecular creativity, rational design , nature’s molecules still outperform many designed compounds. • The Power of Structure : How privileged : GPCR-focused chemical design is evolving—fast. Whether you’re designing the next assay, scouting a new therapeutic angle, or exploring career pivots

Whether you’re early in your career or pushing the edge of MoA design, weekly lesson help you apply key Terry Kenakin   Terry’s Corner is your space focused on GPCR pharmacology designed just for you.   With strong signal stability, HTS compatibility, and broad assay versatility, CELT-419 is designed for oncogenic signaling in lymphoid neoplasms, and its disruption boosts sensitivity to the apoptosis-inducing drug GPCR Team

Watch Episode 175 From failed assays to breakthroughs in GPCR modeling , Dr. When he returned to Sweden for his PhD, he focused on small molecule design. behavior post hoc, his group began developing workflows and strategies that could drive experimental design predictions—a sentiment that highlights the skepticism that still exists around modeling in some corners of drug For early-career researchers, the takeaway is direct: GPCR drug discovery will increasingly depend on

Target-based screening is now a fundamental pillar of drug development, and GPCRs are key targets for This makes them very useful for GPCR drug discovery, since receptors are a lot bigger than their small Optimizing GPCR Drug Discovery with Fluorescence Polarization: Key Advantages and Future Perspectives Compatible with various sources of GPCRs. Contact us  to drive further advancements in GPCR drug discovery!  

Unlocking the Puzzle: The Importance of Precision in GPCR Programs and the Hidden Costs of Overlooking Hiring Won’t Save Your GPCR Drug Discovery Program When a drug discovery program stalls, the default Bad Data Management Is Undermining Your GPCR Drug Discovery Team The real problem isn’t competence. Without a unified drug discovery data management  pipeline, teams waste hours cleaning, reconciling, Build Precision Systems for GPCR Drug Discovery The only way out for GPCR drug discovery programs isn

For drug hunters working at the GPCR interface, the difference between a successful lead and a dead-end For GPCR drug discovery, those hidden details can determine whether a compound advances or stalls.  can uncover hidden efficacy, silent antagonism, or even inverse agonism. ✅ Practical insights into designing The Hidden Lever in GPCR Research In GPCR pharmacology, the conversation often centers on ligand properties—affinity In an era of accelerated GPCR-targeting innovation, these advantages define which programs advance and

Enhancing scientific exploration by concentrating on understanding inhibition to advance GPCR drug discovery This Week’s GPCR Intelligence: Every drug you design will meet an enzyme before it meets its receptor Whether you’re designing a ligand, optimizing ADME, or predicting PK, enzyme inhibition defines what When “inhibition” becomes activation—and how that insight fuels next-gen therapeutic design. field 🧠 Designed for researchers at every career stage

Rational Drug Design One immediate application of this research lies in rational drug design . This distinction is essential for designing drugs that selectively target these residues to achieve desired For example, orthosteric drug design —in which drugs bind to the receptor’s primary active site—can now Evolutionary Insights and Drug Design From an evolutionary standpoint, the study reveals that residues Conclusion In summary, the findings of this study have significant implications for drug design, personalised

Every September, Boston welcomes the global biotech and drug discovery community. drug discovery. Their expertise, collaboration, and commitment to quality make them an indispensable partner in modern drug Axxam Axxam is a leading provider of integrated discovery services, supporting the entire drug discovery important and validated target classes in drug discovery.